Clinical Trial Update: High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) [Phase 3]

View source ↗

Summary

Phase 3 trial HEIRLOOM evaluating high-dose aflibercept switching (load vs maintain) for wet/neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Clinique de Retine de l'est | Conditions: Wet Age-related Macular Degeneration (wAMD) | Phase 3 | Status: NOT_YET_RECRUITING